Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study
S. Monestier(Hôpital de la Timone), Brigitte Dréno(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), S. Dalac‐Rat(Centre Hospitalier du Mans), J.-P. Arnault(Centre National de la Recherche Scientifique), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), E. Hainaut(Centre Hospitalier Universitaire de Poitiers), Henri Montaudié(Hôpital l'Archet), Émilie Varey(Inserm), Thomas Jouary(Hôpital Saint-André), F. Skowron, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nabahet Ameur(Bristol-Myers Squibb (France)), B. Guillot(Université de Montpellier), P. Combemale(Centre Léon Bérard), Yannick Le Corre(Université Nantes Angers Le Mans), Nicolás Meyer(Université Toulouse III - Paul Sabatier), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Caroline Robert(Centre National de la Recherche Scientifique), Anne‐Bénédicte Duval Modeste(Hôpital Charles-Nicolle), Amir Khammari(Inserm), N. Bénéton(Centre Hospitalier du Mans)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k